StockNews.com Upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) to "Strong-Buy" : vimarsana.com

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Sunday. Other analysts have also issued reports about the stock. Canaccord Genuity Group reissued a “sell” rating and set a $371.00 target price on shares of Vertex […]

Related Keywords

Ourania Tatsis , Sanfordc Bernstein , Investment Advisers , Vertex Pharmaceuticals Incorporated , Barclays , Institutional Trading Of Vertex Pharmaceuticals , Cantor Fitzgerald , Plato Investment Management Ltd , News Ratings For Vertex Pharmaceuticals Daily , Montchanin Asset Management , Analyst Recommendations For Vertex Pharmaceuticals , Canaccord Genuity Group , Vertex Pharmaceuticals , Strategic Wealth Partners Ltd , Vertex Pharmaceuticals Company Profile , Vertex Pharmaceuticals Stock , Get Free Report , Genuity Group , Wealth Partners , Asset Management , Investment Management Ltd , Pharmaceuticals Incorporated , Vertex Pharmaceuticals Daily ,